Taken together, our results demonstrate that the HSP90A inhibition enhances response to ICB therapy by reversing immune resistance of tumor cells to CTL killing, which switches immune phenotypes from non-T cell inflamed to T cell-inflamed tumors. This evidence concerns the gene HSP90AA1 and neoplasm.